Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients

被引：26
|
作者：
Taniyama, M
Ohbayashi, S
Narita, M
Nakazawa, R
Hasegawa, S
Azuma, N
Teraoka, S
Ota, K
Yamauchi, S
Margolin, SB
机构：
[1] NARITA MEM HOSP, DEPT INTERNAL MED, TOYOHASHI, AICHI 441, JAPAN
[2] TOKATSU CLIN HOSP, DEPT NEPHROL, MATSUDO, CHIBA 271, JAPAN
[3] TOKYO WOMENS MED COLL, DEPT SURG, KIDNEY CTR, SHINJUKU KU, TOKYO 162, JAPAN
[4] KDL INC, CHIYODA KU, TOKYO, JAPAN
[5] MARNAC INC, DALLAS, TX 75225 USA
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1997年 / 52卷 / 01期
关键词：
pirfenidone; peritoneal sclerosis; haemodialysis;
D O I：
10.1007/s002280050252
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：77 / 78
页数：2
相关论文
共 50 条
  • [21] Antifibrotic Effect of Pirfenidone on Human Pterygium Fibroblasts
    Lee, Kihwang
    Lee, Sun Young
    Park, So Yean
    Yang, Hongseok
    CURRENT EYE RESEARCH, 2014, 39 (07) : 680 - 685
  • [22] Pirfenidone -: Deskar® -: Treatment of renal failure -: Antifibrotic
    不详
    DRUGS OF THE FUTURE, 2001, 26 (06) : 606 - 607
  • [23] Novel pirfenidone derivatives: Potent antifibrotic agents
    Ma, Zhen
    Yu, Chenhuan
    Chen, Qi
    Huang, Wenhai
    Wang, Zunyuan
    Zhang, Chixiao
    Shen, Zhengrong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [24] Quinine pharmacokinetics in chronic haemodialysis patients
    Roy, L
    Bannon, P
    Villeneuve, JP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (06) : 604 - 609
  • [25] Antifibrotic Agent, Pirfenidone, Inhibits Pancreatic Stellate Cells and Tumor-Stromal Interaction in Pancreatic Cancer
    Kozono, S.
    Ohuchida, K.
    Eguchi, D.
    Fujiwara, K.
    Zhao, M.
    Cui, L.
    Mizumoto, K.
    Tanaka, M.
    PANCREAS, 2012, 41 (08) : 1377 - 1377
  • [26] Pirfenidone as a potential antifibrotic injectable for Dupuytren's disease
    Panigrahi, Suchitra
    Barry, Amanda
    Multner, Scott
    Kasting, Gerald B.
    Figueroa, Julio A. Landero
    Satish, Latha
    Kumari, Harshita
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2022, 27 (02) : 242 - 250
  • [27] Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo
    Ma, Zhen
    Zhao, Cungang
    Chen, Qi
    Yu, Chenhuan
    Zhang, Huanhuan
    Zhang, Zhimin
    Huang, Wenhai
    Shen, Zhengrong
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 53 : 100 - 106
  • [28] Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents
    Ma, Zhen
    Pan, Youlu
    Huang, Wenhai
    Yang, Yewei
    Wang, Zunyuan
    Li, Qin
    Zhao, Yin
    Zhang, Xinyue
    Shen, Zhengrong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 220 - 223
  • [29] Effect of pirfenidone, a novel antifibrotic agent, on PDGF-induced intracellular signaling in rat hepatic stellate cells
    Di Sario, A
    Bendia, E
    Baroni, GS
    Saccomanno, S
    Ridolfi, R
    Ugili, U
    Trozzi, L
    Jezequel, AM
    Benedetti, A
    JOURNAL OF HEPATOLOGY, 2000, 32 : 79 - 79
  • [30] Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis
    Papaioannou, MG
    Marinaki, S
    Pappas, M
    Stamatiadis, D
    Giamarellos-Bourboulis, EJ
    Giamarellou, H
    Stathakis, C
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (03) : 233 - 236
12345